Servier's Protelos and Osseor are still important despite VTE and skin concerns, says EMA
This article was originally published in Scrip
Servier's bone drugs, Protelos and Osseor (strontium ranelate) is still an "important treatment" for women with osteoporosis, says the European Medicines Agency. The drugs' benefit: risk profile remains favourable, but the medicine is no longer to be recommended for certain patients, while warnings on serious skin reaction are to be updated.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.